BJMO - 2021, issue 3, march 2021
Catherine Percy , Géraldine Rosier , Claire Barani , Fanny Collette , Laurence Faugeras , Lionel D'Hondt
Background: Metronomic chemotherapy consists of low-dose oral chemotherapy given continuously. The antitumor activity is supposed to be due to antiangiogenic and immunomodulation effects. This retrospective analysis was done to evaluate the benefit-risk balance of this treatment in palliative setting for unselected metastatic cancer patients.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
